Atea Pharmaceuticals (AVIR) Liabilities and Shareholders Equity (2019 - 2026)

Atea Pharmaceuticals' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $267.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 39.3% year-over-year to $267.1 million; the TTM figure through Mar 2026 stood at $1.3 billion (down 30.91% YoY), while the FY2025 annual figure was $315.2 million, down 32.16% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $267.1 million, down from $315.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $717.2 million in Q1 2022, with the low at $267.1 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $553.0 million (2024), against an average of $529.9 million.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity declined 9.84% in 2023, then tumbled 39.3% in 2026.
• Atea Pharmaceuticals' Liabilities and Shareholders Equity stood at $666.7 million in 2022, then slipped by 10.76% to $595.0 million in 2023, then slipped by 21.9% to $464.7 million in 2024, then tumbled by 32.16% to $315.2 million in 2025, then dropped by 15.27% to $267.1 million in 2026.
• Business Quant data shows AVIR's Liabilities and Shareholders Equity at $267.1 million in Q1 2026, $315.2 million in Q4 2025, and $343.0 million in Q3 2025.